Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
| 22.42 | |
| 22.81 | |
| - | |
| 22.96 | |
| 22.06 | |
| 18.21-52.81 | |
| 1 620 M | |
| 63 515 K | |
| 188 M | |
| 1.51 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Initiative initially funded by $10 million grant from the Bill & Melinda Gates Foundation NEW YORK, July 26, 2024--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computationa...
Omnicell (OMCL) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
